United States Biotechnology & Medical Research

Xeris Pharmaceuticals Inc (XERS)

Track

Track

Ticker: XERS Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders

Similar companies

View all Biotechnology & Medical Research companies
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
PRESTRELSKI STEVEN Chief Scientific Officer Officer
Transaction date
Planned sale
Price
91.42
Quantity 47,053 -16.9%
Value US$2,818,856
PRESTRELSKI STEVEN Chief Scientific Officer Officer
Transaction date
Planned sale
Price
61.20
Quantity 85,695 -2.1%
Value US$1,984,103
3.8
Edick Paul R See Remarks Executive Director
Transaction date
Purchase
Price
244.53
Quantity 38,859 -49.7%
Value US$1,575,577
3.8
Shannon John Patrick Jr See Remarks Officer
Transaction date
Purchase
Price
3.55
Quantity 22,000 +23.0%
Value US$77,994
3.8
Shannon John Patrick Jr See Remarks Officer
Transaction date
Purchase
Price
3.20
Quantity 7,886 +9.0%
Value US$25,219
3.8
Edick Paul R See Remarks Executive Director
Transaction date
Purchase
Price
3.00
Quantity 33,000 +9.0%
Value US$99,000
3.1
Hecht Beth See Remarks Officer
Transaction date
Purchase
Price
1.97
Quantity 4,000 +7.5%
Value US$7,880
3.1
Hecht Beth See Remarks Officer
Transaction date
Purchase
Price
4.15
Quantity 4,000 +98.0%
Value US$16,600
3.8
Edick Paul R See Remarks Executive Director
Transaction date
Purchase
Price
4.15
Quantity 20,000 +12.3%
Value US$83,000
Deutsch Barry M. See Remarks Officer
Transaction date
Purchase
Price
4.15
Quantity 9,639 +32.4%
Value US$40,002
3.8
Shannon John Patrick Jr See Remarks Officer
Transaction date
Purchase
Price
4.15
Quantity 12,048 +114.1%
Value US$49,999
JOHNSON KENNETH ERLAND See Remarks Officer
Transaction date
Purchase
Price
4.15
Quantity 2,410 +65.0%
Value US$10,002
PRESTRELSKI STEVEN Chief Scientific Officer
Transaction date
Planned sale
Price
5.50
Quantity 10,000 -2.3%
Value US$54,992
3.8
Edick Paul R See Remarks Executive Director
Transaction date
Purchase
Price
8.55
Quantity 17,935 +11.6%
Value US$153,283
PRESTRELSKI STEVEN Chief Scientific Officer
Transaction date
Planned sale
Price
7.97
Quantity 10,000 -2.2%
Value US$79,746
PRESTRELSKI STEVEN Chief Scientific Officer
Transaction date
Planned sale
Price
12.70
Quantity 38 -0.0%
Value US$483
PRESTRELSKI STEVEN Chief Scientific Officer
Transaction date
Planned sale
Price
12.04
Quantity 9,962 -2.1%
Value US$119,913
PRESTRELSKI STEVEN Chief Scientific Officer
Transaction date
Planned sale
Price
9.56
Quantity 10,000 -2.1%
Value US$95,649
3.8
Edick Paul R See Remarks Executive Director
Transaction date
Purchase
Price
9.12
Quantity 30,000 +24.0%
Value US$273,585
JOHNSON KENNETH ERLAND See Remarks Officer
Transaction date
Purchase
Price
10.00
Quantity 1,000 +44.5%
Value US$10,000
Deutsch Barry M. See Remarks Officer
Transaction date
Purchase
Price
10.00
Quantity 5,000 +21.5%
Value US$50,000
3.1
Hecht Beth See Remarks Officer
Transaction date
Purchase
Price
10.00
Quantity 2,500 +inf%
Value US$25,000
3.2
Redmile Group, LLC Large shareholder
Transaction date
Purchase
Price
10.00
Quantity 588,000 +24.4%
Value US$5,880,000
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.00
Quantity 1,351 -0.2%
Value US$20,265
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.11
Quantity 5,890 -0.7%
Value US$88,986
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.00
Quantity 9,409 -1.1%
Value US$141,135
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.00
Quantity 400 -0.0%
Value US$6,000
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.07
Quantity 4,998 -0.6%
Value US$75,308
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.14
Quantity 6,210 -0.7%
Value US$94,028
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.00
Quantity 828 -0.1%
Value US$12,420
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.08
Quantity 76,820 -8.0%
Value US$1,158,254
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
15.03
Quantity 5,425 -0.6%
Value US$81,563
2.8
Flynn James E Large shareholder
Transaction date
Sale
Price
16.35
Quantity 32,199 -3.2%
Value US$526,376
PRESTRELSKI STEVEN Chief Scientific Officer
Transaction date
Planned sale
Price
17.20
Quantity 7,700 -1.6%
Value US$132,459
PRESTRELSKI STEVEN Chief Scientific Officer Officer
Transaction date
Planned sale
Price
0.00
Quantity 2,300
Value US$0
PRESTRELSKI STEVEN Chief Scientific Officer Officer
Transaction date
Sale
Price
15.82
Quantity 15,720 -3.1%
Value US$248,738
Redmile Group, LLC
Transaction date
Purchase
Price
15.00
Quantity 666,668 +38.2%
Value US$10,000,020
Flynn James E Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 624,333 +71.4%
Value US$9,364,995
Flynn James E Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 125,667 +14.4%
Value US$1,885,005
Palmetto Partners, Ltd. Large shareholder
Transaction date
Purchase
Price
15.00
Quantity 150,000 +7.7%
Value US$2,250,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2021-01-15 2021-01-13 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer

Officer
47,053 -16.9%
91.42
US$2,818,856 		47,053 -16.9% 91.42 US$2,818,856
2021-01-12 2021-01-11 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer

Officer
85,695 -2.1%
61.20
US$1,984,103 		85,695 -2.1% 61.20 US$1,984,103
2020-12-10 2020-12-09 B Purchase
3.8
Edick Paul R

See Remarks

Executive Director
38,859 -49.7%
244.53
US$1,575,577 		38,859 -49.7% 244.53 US$1,575,577
2020-05-14 2020-05-13 B Purchase
3.8
Shannon John Patrick Jr

See Remarks

Officer
22,000 +23.0%
3.55
US$77,994 		22,000 +23.0% 3.55 US$77,994
2020-05-11 2020-05-08 B Purchase
3.8
Shannon John Patrick Jr

See Remarks

Officer
7,886 +9.0%
3.20
US$25,219 		7,886 +9.0% 3.20 US$25,219
2020-05-11 2020-05-08 B Purchase
3.8
Edick Paul R

See Remarks

Executive Director
33,000 +9.0%
3.00
US$99,000 		33,000 +9.0% 3.00 US$99,000
2020-03-16 2020-03-13 B Purchase
3.1
Hecht Beth

See Remarks

Officer
4,000 +7.5%
1.97
US$7,880 		4,000 +7.5% 1.97 US$7,880
2020-02-18 2020-02-14 B Purchase
3.1
Hecht Beth

See Remarks

Officer
4,000 +98.0%
4.15
US$16,600 		4,000 +98.0% 4.15 US$16,600
2020-02-18 2020-02-14 B Purchase
3.8
Edick Paul R

See Remarks

Executive Director
20,000 +12.3%
4.15
US$83,000 		20,000 +12.3% 4.15 US$83,000
2020-02-18 2020-02-14 B Purchase
Deutsch Barry M.

See Remarks

Officer
9,639 +32.4%
4.15
US$40,002 		9,639 +32.4% 4.15 US$40,002
2020-02-18 2020-02-14 B Purchase
3.8
Shannon John Patrick Jr

See Remarks

Officer
12,048 +114.1%
4.15
US$49,999 		12,048 +114.1% 4.15 US$49,999
2020-02-18 2020-02-14 B Purchase
JOHNSON KENNETH ERLAND

See Remarks

Officer
2,410 +65.0%
4.15
US$10,002 		2,410 +65.0% 4.15 US$10,002
2020-01-14 2020-01-13 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer
10,000 -2.3%
5.50
US$54,992 		10,000 -2.3% 5.50 US$54,992
2019-11-27 2019-11-25 B Purchase
3.8
Edick Paul R

See Remarks

Executive Director
17,935 +11.6%
8.55
US$153,283 		17,935 +11.6% 8.55 US$153,283
2019-10-16 2019-10-11 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer
10,000 -2.2%
7.97
US$79,746 		10,000 -2.2% 7.97 US$79,746
2019-10-16 2019-07-11 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer
38 -0.0%
12.70
US$483 		38 -0.0% 12.70 US$483
2019-10-16 2019-07-11 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer
9,962 -2.1%
12.04
US$119,913 		9,962 -2.1% 12.04 US$119,913
2019-04-12 2019-04-11 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer
10,000 -2.1%
9.56
US$95,649 		10,000 -2.1% 9.56 US$95,649
2019-03-12 2019-03-11 B Purchase
3.8
Edick Paul R

See Remarks

Executive Director
30,000 +24.0%
9.12
US$273,585 		30,000 +24.0% 9.12 US$273,585
2019-02-25 2019-02-19 B Purchase
JOHNSON KENNETH ERLAND

See Remarks

Officer
1,000 +44.5%
10.00
US$10,000 		1,000 +44.5% 10.00 US$10,000
2019-02-22 2019-02-19 B Purchase
Deutsch Barry M.

See Remarks

Officer
5,000 +21.5%
10.00
US$50,000 		5,000 +21.5% 10.00 US$50,000
2019-02-22 2019-02-19 B Purchase
3.1
Hecht Beth

See Remarks

Officer
2,500 +inf%
10.00
US$25,000 		2,500 +inf% 10.00 US$25,000
2019-02-21 2019-02-19 B Purchase
3.2
Redmile Group, LLC
Large shareholder
588,000 +24.4%
10.00
US$5,880,000 		588,000 +24.4% 10.00 US$5,880,000
2019-02-12 2019-02-11 S Sale
2.8
Flynn James E
Large shareholder
1,351 -0.2%
15.00
US$20,265 		1,351 -0.2% 15.00 US$20,265
2019-02-12 2019-02-08 S Sale
2.8
Flynn James E
Large shareholder
5,890 -0.7%
15.11
US$88,986 		5,890 -0.7% 15.11 US$88,986
2019-02-07 2019-02-07 S Sale
2.8
Flynn James E
Large shareholder
9,409 -1.1%
15.00
US$141,135 		9,409 -1.1% 15.00 US$141,135
2019-02-07 2019-02-06 S Sale
2.8
Flynn James E
Large shareholder
400 -0.0%
15.00
US$6,000 		400 -0.0% 15.00 US$6,000
2019-02-07 2019-02-05 S Sale
2.8
Flynn James E
Large shareholder
4,998 -0.6%
15.07
US$75,308 		4,998 -0.6% 15.07 US$75,308
2019-01-30 2019-01-29 S Sale
2.8
Flynn James E
Large shareholder
6,210 -0.7%
15.14
US$94,028 		6,210 -0.7% 15.14 US$94,028
2019-01-30 2019-01-28 S Sale
2.8
Flynn James E
Large shareholder
828 -0.1%
15.00
US$12,420 		828 -0.1% 15.00 US$12,420
2019-01-25 2019-01-25 S Sale
2.8
Flynn James E
Large shareholder
76,820 -8.0%
15.08
US$1,158,254 		76,820 -8.0% 15.08 US$1,158,254
2019-01-25 2019-01-24 S Sale
2.8
Flynn James E
Large shareholder
5,425 -0.6%
15.03
US$81,563 		5,425 -0.6% 15.03 US$81,563
2019-01-25 2019-01-23 S Sale
2.8
Flynn James E
Large shareholder
32,199 -3.2%
16.35
US$526,376 		32,199 -3.2% 16.35 US$526,376
2019-10-16 2019-01-14 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer
7,700 -1.6%
17.20
US$132,459 		7,700 -1.6% 17.20 US$132,459
2019-01-15 2019-01-11 PlS Planned sale
PRESTRELSKI STEVEN

Chief Scientific Officer

Officer
2,300
0.00
US$0 		2,300 0.00 US$0
2019-01-02 2018-12-26 S Sale
PRESTRELSKI STEVEN

Chief Scientific Officer

Officer
15,720 -3.1%
15.82
US$248,738 		15,720 -3.1% 15.82 US$248,738
2018-06-27 2018-06-25 B Purchase Redmile Group, LLC
666,668 +38.2%
15.00
US$10,000,020 		666,668 +38.2% 15.00 US$10,000,020
2018-06-27 2018-06-25 B Purchase Flynn James E Large shareholder
624,333 +71.4%
15.00
US$9,364,995 		624,333 +71.4% 15.00 US$9,364,995
2018-06-27 2018-06-25 B Purchase Flynn James E Large shareholder
125,667 +14.4%
15.00
US$1,885,005 		125,667 +14.4% 15.00 US$1,885,005
2018-06-25 2018-06-25 B Purchase Palmetto Partners, Ltd. Large shareholder
150,000 +7.7%
15.00
US$2,250,000 		150,000 +7.7% 15.00 US$2,250,000
Explore more

More insider trading research around Xeris Pharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America